CN104507308A - 用辅酶q10治疗实体肿瘤的方法 - Google Patents

用辅酶q10治疗实体肿瘤的方法 Download PDF

Info

Publication number
CN104507308A
CN104507308A CN201380040105.3A CN201380040105A CN104507308A CN 104507308 A CN104507308 A CN 104507308A CN 201380040105 A CN201380040105 A CN 201380040105A CN 104507308 A CN104507308 A CN 104507308A
Authority
CN
China
Prior art keywords
dose
coq10
cancer
administered
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380040105.3A
Other languages
English (en)
Chinese (zh)
Inventor
N·R·纳莱恩
J·P·麦库克
P·Y·宋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bo Ge Co Ltd
Original Assignee
Bo Ge Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bo Ge Co Ltd filed Critical Bo Ge Co Ltd
Publication of CN104507308A publication Critical patent/CN104507308A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201380040105.3A 2012-06-01 2013-05-31 用辅酶q10治疗实体肿瘤的方法 Pending CN104507308A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261654245P 2012-06-01 2012-06-01
US61/654,245 2012-06-01
PCT/US2013/043785 WO2013181639A1 (en) 2012-06-01 2013-05-31 Treatment of solid tumors using coenzyme q10

Publications (1)

Publication Number Publication Date
CN104507308A true CN104507308A (zh) 2015-04-08

Family

ID=49673946

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380040105.3A Pending CN104507308A (zh) 2012-06-01 2013-05-31 用辅酶q10治疗实体肿瘤的方法

Country Status (16)

Country Link
US (3) US20140017317A1 (https=)
EP (1) EP2854528B8 (https=)
JP (3) JP6352905B2 (https=)
KR (2) KR20200118233A (https=)
CN (1) CN104507308A (https=)
AU (2) AU2013267166A1 (https=)
BR (1) BR112014029954A2 (https=)
CA (2) CA3090268A1 (https=)
EA (1) EA032345B1 (https=)
ES (1) ES2761449T3 (https=)
IL (1) IL236008B (https=)
IN (1) IN2014DN10734A (https=)
MX (2) MX369768B (https=)
NZ (1) NZ702369A (https=)
SG (1) SG11201407880QA (https=)
WO (1) WO2013181639A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110769818A (zh) * 2017-05-17 2020-02-07 博格有限责任公司 辅酶q10制剂在治疗和预防大疱性表皮松解症中的用途

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010247800A1 (en) 2009-05-11 2011-12-15 Berg Llc Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
MX369768B (es) * 2012-06-01 2019-11-21 Berg Llc Composición farmacéutica de coenzima q10 para usarse en un método para tratar cáncer.
SG10201903112WA (en) * 2013-04-08 2019-05-30 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
KR102370843B1 (ko) 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
US9996463B2 (en) * 2015-11-10 2018-06-12 International Business Machines Corporation Selection and placement of volumes in a storage system using stripes
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
US20170255565A1 (en) * 2016-03-02 2017-09-07 Intel Corporation Method and apparatus for providing a contiguously addressable memory region by remapping an address space
US20200093751A1 (en) * 2016-06-28 2020-03-26 Der-Yang Tien Chemoprotective/chemoactive nanodroplets and methods of use thereof
WO2023099436A1 (en) * 2021-12-01 2023-06-08 Gambro Lundia Ab New dialysis fluid
WO2025087731A1 (en) * 2023-10-24 2025-05-01 Gambro Lundia Ab Compositions comprising insulin and ketones bodies to treat cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102018693A (zh) * 2004-01-22 2011-04-20 迈阿密大学 局部辅酶q10制剂及其使用方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20070104688A1 (en) 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
WO2005048925A2 (en) * 2003-11-14 2005-06-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds
JPWO2008069276A1 (ja) * 2006-12-06 2010-03-25 株式会社カネカ 癌治療剤および発癌抑制剤
CA2680825C (en) 2007-03-22 2013-10-29 Cytotech Labs, Llc Topical formulations having enhanced bioavailability
CN103169973A (zh) * 2007-11-12 2013-06-26 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌
WO2009082607A2 (en) 2007-12-04 2009-07-02 Alnylam Pharmaceuticals, Inc. Targeting lipids
US8247435B2 (en) * 2009-02-19 2012-08-21 Thornthwaite Jerry T Formulations for treating human and animal diseases
AU2010247800A1 (en) * 2009-05-11 2011-12-15 Berg Llc Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
GB0913193D0 (en) 2009-07-29 2009-09-02 Johnson Matthey Plc Deoxygenation process
CN105168135A (zh) * 2010-03-12 2015-12-23 博格有限责任公司 辅酶Q10(CoQ10)的静脉内制剂及其使用方法
US10973763B2 (en) 2011-06-17 2021-04-13 Berg Llc Inhalable pharmaceutical compositions
MX369768B (es) * 2012-06-01 2019-11-21 Berg Llc Composición farmacéutica de coenzima q10 para usarse en un método para tratar cáncer.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102018693A (zh) * 2004-01-22 2011-04-20 迈阿密大学 局部辅酶q10制剂及其使用方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110769818A (zh) * 2017-05-17 2020-02-07 博格有限责任公司 辅酶q10制剂在治疗和预防大疱性表皮松解症中的用途

Also Published As

Publication number Publication date
ES2761449T3 (es) 2020-05-19
MX369768B (es) 2019-11-21
EP2854528B1 (en) 2019-09-18
JP6352905B2 (ja) 2018-07-04
IL236008A0 (en) 2015-02-01
WO2013181639A8 (en) 2014-12-31
HK1208995A1 (en) 2016-03-24
JP2018168164A (ja) 2018-11-01
JP2020183440A (ja) 2020-11-12
KR20150022932A (ko) 2015-03-04
KR102163948B1 (ko) 2020-10-12
IL236008B (en) 2018-08-30
US20220096399A1 (en) 2022-03-31
WO2013181639A1 (en) 2013-12-05
KR20200118233A (ko) 2020-10-14
MX2019013776A (es) 2020-01-30
EP2854528A1 (en) 2015-04-08
EA201492187A1 (ru) 2015-05-29
AU2017202567A1 (en) 2017-05-11
US20170216223A1 (en) 2017-08-03
EP2854528A4 (en) 2016-03-09
BR112014029954A2 (pt) 2017-06-27
US20140017317A1 (en) 2014-01-16
EA032345B1 (ru) 2019-05-31
SG11201407880QA (en) 2014-12-30
JP7225167B2 (ja) 2023-02-20
AU2017202567B2 (en) 2019-06-13
EP2854528B8 (en) 2019-10-23
CA2875150C (en) 2020-10-27
CA2875150A1 (en) 2013-12-05
NZ702369A (en) 2016-12-23
CA3090268A1 (en) 2013-12-05
MX2014014492A (es) 2015-05-12
JP2015518056A (ja) 2015-06-25
IN2014DN10734A (https=) 2015-09-04
AU2013267166A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
JP7225167B2 (ja) コエンザイムｑ１０を用いた固形腫瘍の治療
US11452699B2 (en) Method of treating or preventing tumors of the central nervous system
US12303471B2 (en) Methods of treatment of temozolomide-resistant glioma using coenzyme Q10
CN105338973A (zh) 使用辅酶q10联合疗法治疗癌症
CN105705162A (zh) 通过持续输注辅酶q10来治疗癌症的方法
HK1208995B (en) Treatment of solid tumors using coenzyme q10
HK1194361B (en) Treating central nervous system tumors with coenzyme q10
HK1194361A (en) Treating central nervous system tumors with coenzyme q10

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150408